Avisa Diagnostics (XCNQ:AVBT) FCF Margin % : 0.00% (As of Jun. 2021)

View and export this data going back to 2010. Start your Free Trial

What is Avisa Diagnostics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Avisa Diagnostics's Free Cash Flow for the three months ended in Jun. 2021 was C$-0.71 Mil. Avisa Diagnostics's Revenue for the three months ended in Jun. 2021 was C$0.00 Mil. Therefore, Avisa Diagnostics's FCF Margin % for the quarter that ended in Jun. 2021 was 0.00%.

As of today, Avisa Diagnostics's current FCF Yield % is 0.00%.

The historical rank and industry rank for Avisa Diagnostics's FCF Margin % or its related term are showing as below:

XCNQ:AVBT' s FCF Margin % Range Over the Past 10 Years
Min: -332.02 Med: 0 Max: 0
Current: -332.02

XCNQ:AVBT's FCF Margin % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -7.06 vs XCNQ:AVBT: -332.02

Avisa Diagnostics FCF Margin % Historical Data

The historical data trend for Avisa Diagnostics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avisa Diagnostics FCF Margin % Chart

Avisa Diagnostics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

FCF Margin %

Get a 7-Day Free Trial

-1,156.70

-163.80

-162.64

Avisa Diagnostics Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
FCF Margin %	Get a 7-Day Free Trial															-158.09	-	-	-	-

Competitive Comparison of Avisa Diagnostics's FCF Margin %

For the Medical Devices subindustry, Avisa Diagnostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avisa Diagnostics's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avisa Diagnostics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Avisa Diagnostics's FCF Margin % falls into.

Avisa Diagnostics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Avisa Diagnostics's FCF Margin for the fiscal year that ended in Dec. 2020 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2020 )	/	Revenue (A: Dec. 2020 )
	=	-0.579	/	0.356
	=	-162.64 %

Avisa Diagnostics's FCF Margin for the quarter that ended in Jun. 2021 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2021 )	/	Revenue (Q: Jun. 2021 )
	=	-0.711	/	0
	=	%

Avisa Diagnostics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Avisa Diagnostics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Avisa Diagnostics (XCNQ:AVBT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avisa Diagnostics Inc (XCNQ:AVBT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1660A Old Pecos Trail, Santa Fe, NM, USA, 87505

Website

https://www.avisapharma.com

Avisa Diagnostics Inc is a clinical-stage medical device company developing the Avisa BreathTest, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its proprietary drug substrates. The company has established clinical proof-of-concept through trials in cystic fibrosis, tuberculosis and community acquired pneumonia, which demonstrated positive safety and clinical efficacy results. Avisa is planning pivotal trials in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia and plans to submit Investigational Device Exemption applications to the U.S. FDA for these trials.

Avisa Diagnostics (XCNQ:AVBT) Headlines

No Headlines